MiSight 1 day contact lens seven-year clinical trial findings indicate myopia control is sustained as mean axial elongation data show no evidence of rebound effect 12 months after treatment cessation, CooperVision reported.
In the study’s seventh year, participants were transitioned from MiSight 1 day to a single-vision contact lens to evaluate if treatment gains were retained. Myopic progression then occurred only at anticipated ‘age-normal’ levels, rather than at an accelerated rate that would offset prior myopia-control gains and indicate a rebound effect, said Paul Chamberlain, principal investigator and CooperVision director of research.
Chamberlain added that this illustrates the potential of the lenses for children of different ages and with different levels of myopia, regardless of when they start treatment. “With these results, eyecare professionals should be even more confident in prescribing MiSight 1 day,” he said.
